Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats

Table 3 Effects of silymarin on H-MDA, H-GSH and Plasma TAC

GROUP	H-MDA (nmol/g tissue)	H-GSH (μmol/g tissue)	P-TAC (nmol AAEAC/L)
NC	52.65 ± 3.49	37.98 ± 1.07	0.933 ± 0.001
FC	67.60 ± 3.21***	33.93 ± 0.91***	0.927 ± 0.002***
SC	56.21 ± 4.99 ^##	36.53 ± 0.89 ^##	0.931 ± 0.002 ^##
FTH	59.77 ± 5.40 ^#	35.49 ± 0.98	0.930 ± 0.002 ^#
FFH	57.63 ± 4.48 ^##	36.35 ± 0.93 ^##	0.930 ± 0.001^#

At the end of the experiment the H-MDA, H-GSH and Plasma TAC were measured. NC normal control, FC fructose control, SC silymarin control, FTH fructose + 200 mg/kg silymarin, FFH fructose + 400 mg/kg silymarin. Data were presented as mean ± SD. N = 6 for each group. *** p < 0.001 vs. NC and ^# p < 0.05 vs. FC; ^## p < 0.01 vs. FC

ISSN: 2662-7671